Tau PET as Progression Marker: It’s the Spread, Not the Brightness
The spatial extent of tau pathology better correlates with disease severity, and stages disease more accurately, than does tangle load. Trials are starting to use this measure.
The spatial extent of tau pathology better correlates with disease severity, and stages disease more accurately, than does tangle load. Trials are starting to use this measure.
Decreased lysosomal efficiency could result from shifts in endosomal recycling.
DIAN-TU explains how it selects APP, PSEN1, and PSEN2 genetic variants for clinical trial inclusion; unveils a list.
After one TREM2 agonist antibody nose-planted, a new batch of therapies appear safe so far in first-in-human data. The drugs exert different effects on the receptor and soluble TREM2.
In mouse models, the microglial receptor counteracts their hyperexcitability. Both transmembrane and soluble TREM2 appear to help with this.
At AD/PD, scientists reported that TREM2 expressed on plaque-associated microglia becomes desensitized to agonist antibodies. They also suspect the receptor calms hyperactive neurons.
Drawing in researchers in academia, pharma, and AI companies, a nascent consortium aims to speed up discoveries in complex diseases. Smaller AI projects report data at AD/PD.
Several tracers detect the low level of α-synuclein aggregates present in sporadic disease. None are ready for clinical use.
Scientists can now peek at pathology in people living with sporadic Parkinson’s disease. In pilot studies, several tracers light up the sparse aggregates in the substantia nigra of these patients. All the candidates still need tweaking, but the rapid progress suggests a reliable a-synuclein tracer is not far off.
New in last 7 days
Latest Comments